Sara Hurvitz, MD, Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses the HER2CLIMB-02 trial (NCT02614794), whose aim was to assess the safety and efficacy of a combined tucatinib and TDM-1 therapy in previously treated HER2-positive metastatic breast cancer patients. When added to TDM-1, tucatinib, a tyrosine kinase inhibitor, showed improved response rates, particularly in patients with a history of CNS metastasis. Encouraging progression-free survival (PFS) and overall survival (OS) rates were also observed. At the San Antonio Breast Cancer Symposium (SABCS) 2020, Dr Hurvitz discusses the ongoing, Phase III HER2CLIMB-02 study (NCT03975647) evaluating tucatinib vs. placebo in combination with T-DM1 in patients with advanced or metastatic HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).